Biofrontera 8/7/2026 Earnings Report

Biofrontera EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.11
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Biofrontera Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $9.50 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Biofrontera Announcement Details

• Date: 8/7/2026
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Biofrontera (NASDAQ:BFRIW) AG is a biopharmaceutical company headquartered in Leverkusen, Germany, specializing in the development, manufacture and commercialization of dermatology products. Founded in 1997, the company focuses on therapies for skin diseases through innovative drug and device combinations. Its core business centers on photodynamic therapy, where a photosensitizing agent is activated by a specialized light source to treat precancerous and cancerous skin conditions.

The company’s flagship product, Ameluz, is a topical formulation of aminolevulinic acid used in conjunction with the BF-RhodoLED irradiation device. This product duo is approved in Europe and the United States for the treatment of actinic keratosis and superficial basal cell carcinoma. Biofrontera also markets other dermatological products in selected markets, working with distribution partners to reach patients across key regions.

Biofrontera serves markets in the European Union, the United States and other territories through a combination of direct sales operations and strategic partnerships. The company’s US subsidiary, established in 2016, supports clinical development and commercialization efforts in North America. Its management team comprises experienced professionals in pharmaceutical development, regulatory affairs and specialty dermatology.